Replies to post #381703 on NorthWest Biotherapeutics Inc (NWBO)

[exwannabe]

pqr, the Cognate/CRL service agreement is gone.

We can discuss when and why if you wish, but it is certain.

1) Form the FY2020 10-K (page 28. Note 5)

We have possible contingent obligations to pay certain fees to contract manufacturers if we shut down or suspend programs.

For a shut down or suspension of the DCVax-L program at Advent, the Company must give 12 months’ advance notice. During the notice period services would still be provided. Minimum required payments for this notice period total approximately £3.8 million ($5 million).

As of December 31, 2020, no shut-down or suspension fees were triggered.

Manufacturing Services Agreements

The Company has a manufacturing services agreement with Advent BioServices in the U.K.

Advent listed, Cognate not. Last year both Advent and Cognate were listed.

2) Form the FY2019 10K:

We negotiated a new agreement with Cognate for production of DCVax-Direct products in 2019, and we will need to negotiate a new agreement with Cognate in 2020 for production of DCVax-L products for commercial purposes and new programs.

So they thought the contract needed to be redone, and it never was.

EDIT:

Our intention is for the U.K. facility to manufacture DCVax products for both the UK and other regions. However, this may not turn out to be feasible, for regulatory, operational and/or logistical reasons. It is also unclear whether or how Brexit will affect or interfere with these plans in regard to Europe.

[ATLnsider]

Thanks pqr